Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR ...

Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster ...

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...

Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...